Effects of TNP-470 on Prostate-Specific Antigen Levels
Author Information
Author(s): Horti J, Dixon S C, Logothetis C J, Guo Y, Reed E, Figg W D
Primary Institution: Medicine Branch, Division of Clinical Sciences, National Cancer Institute
Hypothesis
Does TNP-470 or its metabolite AGM-1883 alter PSA secretion in patients with androgen-independent prostate cancer?
Conclusion
TNP-470 and AGM-1883 both increase PSA levels, complicating the use of PSA as a clinical marker.
Supporting Evidence
- TNP-470 inhibits capillary growth in several angiogenesis models.
- PSA secretion per cell was induced 1.1- to 1.5-fold following TNP-470 exposure.
- PSA transcription was increased 1.4-fold after exposure to TNP-470.
- Androgen receptor transcription was induced 1.2-fold after exposure to TNP-470.
Takeaway
This study found that a drug called TNP-470 makes a protein called PSA increase in the blood, which could make it harder for doctors to use PSA to check for prostate cancer.
Methodology
The study measured PSA secretion and transcriptional levels in response to TNP-470 and AGM-1883 in a phase I trial.
Participant Demographics
Patients with androgen-independent prostate cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website